Major drugmakers and top agencies alike earned their flowers at the annual Fierce Pharma Marketing Awards gala in ...

GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk.  | GSK is ...

GSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid what a spokesperson said is ...

GSK plans to take the TCE to Phase I clinical trials in multiple myeloma during 2027.

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over currently available ...

John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. Lizzy led STAT’s coverage of the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

GlaxoSmithKline Pharma in India is moving on vaccines, pricing and R&D shifts just as global GSK trades near key levels. Here is how the India-listed unit could matter for US portfolios holding GSK ...

Hengrui Pharma Sunday said that it has entered into agreements with GlaxoSmithKline (NYSE:GSK) to develop up to 12 innovative medicines, adding significant value to the globalization strategy of ...

Nov 3 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported slightly higher second-quarter profit on Thursday, led by steady demand for its specialty medicine portfolio ...